Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A4UW
|
|||
| Former ID |
DIB011513
|
|||
| Drug Name |
BAY-86-7548
|
|||
| Synonyms |
Bombesin-68Ga-labeled tracer (PET/CT cancer imaging), Bayer
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Bayer AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bombesin receptor (BS) | Target Info | Enhancer | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01205321) PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun;54(6):867-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.